Replies to post #189547 on Biotech Values

[hirogen]

OCRX-

Given that some sell-side analysts are not facile with statistics and tend toward pumping, I’m not sure the BMO analyst didn’t mean to imply that that the power of the trial had been increased to more than the 80% it was originally thought to have.

Fair point on the pumping - I mean $26 price target, wow! I don't hold a position currently, but with pps in the low 4's, might be worth a gamble for a small position on expectations riding into final results.